Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.57 |
| ▸ | NPY1R | P25929 | 8/20 | 0.57 |
| ▸ | NPY2R | P49146 | 6/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757876 | 0.92 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30901129 | 0.91 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29932214 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29483767 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL29625340 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL7119638 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL29641074 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL30608889 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL30036967 | 0.90 | NPY4R (0.68) | NPY4RNPY1RNPY2RNPY5RCHRNA1 | |
| SCHEMBL30143658 | 0.90 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5RCHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | NPY4R 379/4885NPY1R 144/4885NPY2R 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.